The company reported FY GAAP EPS of ¥104.99 and a 7.1% decline in core operating profit to ¥55.14 billion.
Santen Pharmaceutical Co. reported full-year revenue of ¥291.62 billion, exceeding estimates by $289.8 billion. GAAP earnings per share stood at ¥104.99 for the fiscal year.
Core operating profit fell 7.1% year-over-year to ¥55.14 billion, while overseas sales contributed 57.7% of total revenue. The company allocated ¥31.78 billion to R&D for new ophthalmic treatments.
Global demand for ophthalmic products remained robust, offsetting weaker domestic performance.